Alector reports Q1 EPS (41c), consensus (46c)

Reports Q1 revenue $3.67M, consensus $4.25M. “With cash runway extending into the second half of 2027, Alector (ALEC) is advancing a portfolio of drug candidates toward novel as well as validated targets for people living with neurodegenerative diseases,” said Arnon Rosenthal, Chief Executive Officer of Alector. “We remain on track to report topline results from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation in the fourth quarter of 2025, and we have completed enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer’s disease. This progress reinforces our commitment to developing meaningful therapies for people living with neurodegeneration.”